期刊文献+

端粒酶与凋亡相关蛋白在卵巢交界性肿瘤中的表达 被引量:3

Significance of Expression of hTERT and Apoptosis Related Protein (bcl-2 and caspase-3) in Borderline Epithelial Ovarian Tumors
下载PDF
导出
摘要 目的:探讨端粒酶蛋白亚单位(hTERT)与凋亡相关蛋白(bcl-2、caspase-3)在卵巢上皮性交界性肿瘤中的表达及临床意义。方法:选取天津市肿瘤医院病理科存档的卵巢上皮性交界性肿瘤41例,采用免疫组化SP法检测hTERT、bcl-2与caspase-3在肿瘤组织中的表达,与22例良性、30例恶性肿瘤进行比较,并探讨三者间表达的相关性。结果:1)hTERT在卵巢交界性肿瘤中阳性率为46.3%,而良性与恶性肿瘤分别为36.4%,73.3%,与交界性肿瘤相比,恶性肿瘤阳性率明显升高(P=0.023),而良性肿瘤与之的差异无统计学意义(P=0.446)。2)bcl-2和caspase-3在卵巢交界性肿瘤中阳性率为58.5%和73.2%,良性与恶性肿瘤分别为59.1%、72.7%和86.7%、43.3%,其中bcl-2的阳性率在交界性肿瘤中明显低于恶性肿瘤(P=0.010),caspase-3反之(P=0.011);但它们在交界性肿瘤中的表达无相关性(r=-0.063,P>0.05),且二者在交界性与良性肿瘤间的差异无统计学意义(P=0.966,0.970)。3)对93例卵巢肿瘤研究发现,hTERT与bcl-2蛋白表达无相关性(r=0.037,P>0.05);hTERT与caspase-3表达呈显著负相关(χ2=4.8109,r=-0.227,P<0.05)。结论:hTERT蛋白表达可以反映端粒酶活性与hTERTmRNA水平,与凋亡相关蛋白(bcl-2、caspase-3)的联合检测可进一步判断卵巢交界性肿瘤良恶性。 Objective: To study the significance of expression of the catalytic subunit of human telomerase hTERT and apoptosis related protein (bcl-2, caspase-3) in borderline epithelial ovarian tumors. Methods: Forty-one cases of borderline epithelial ovarian tumors were studied which were admitted to the Tianjin Cancer Institute and Hospital. hTERT, bcl-2 and caspase-3 were analyzed using immunohistochemistry in formalin-fixed paraffin-embedded tissue. Their status were compared to twenty-two benign and thirty malignant tumors. Results: ⑴ Of the borderline ovarian tumors, the positive expression rate of hTERT was 46.3% which was significantly lower than those of malignant(73.3%) tumors (P=0.023), but the difference between the borderline and benign ovarian tumors was not significant(P=0.446). ⑵ Of the borderline ovarian tumors, the positive expression rate of bcl-2 and caspase-3 was 58.5%and 73.2%, while in the benign and malignant tumors was 59.1%and 72.7%, 86.7% and 43.3%, respectively. Compared to borderline tumors ,the expression rate of bcl-2 and caspase-3 in malignant tumors was significantly higher or lower(P=0.010,0.011), but there was no correlation between expressions of bcl-2 and caspase-3 in borderline ovarian tumors(r=-0.063, P>0.05). And the differences of them between benign and borderline tumors were not significant(P=0.966, 0.970). ⑶ Of the ninety-three ovarian tumors, there was no correlation between expressions of hTERT and bcl-2(r=0.037, P>0.05); but there was significantly reverse correlation between expressions of hTERT and caspase-3 (r=-0.227, P<0.05). Conclusion: These data suggest that detecting hTERT may reflect telomerase activity and the level of hTERTmRNA, co-examination of hTERT and apoptosis related protein (bcl-2 and caspase-3) may contribute to estimating the malignant potential of borderline ovarian tumors. So they possibly become new markers to distinguish a subpopulation with the potential to develop invasive carcinomas.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2004年第3期149-152,共4页 Chinese Journal of Clinical Oncology
关键词 卵巢肿瘤 交界性 端粒酶蛋白亚单位(hTERT)凋亡 Ovarian tumor Borderline tumor hTERT Apoptosis Protein expression
  • 相关文献

参考文献4

二级参考文献15

  • 1张静如.中国共产党与社会现代化[J].北京师范大学学报(社会科学版),1991(3):1-7. 被引量:14
  • 2Burger AM, Bibby MC, Double JA. Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer, 1997,75: 516-522.
  • 3Weinrich SL, Pruzan R, Ma L, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet, 1997, 17:498-502.
  • 4Liu Y, Snow BE, Hande MP, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol, 2000,10:1459-1462.
  • 5Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet, 1998, 18: 65-68.
  • 6Koyanagi Y, Kobayashi D, Yajima T, et al. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemia cells. Anticancer Res,2000, 20, 773-778.
  • 7Erlanger BF. The preparation of antigenic hapten-carrier conjugates: a survey. Methods Enzymol,1980, 70:85-104.
  • 8吴从愿.单克隆抗体的制备、鉴定、提纯、标记和应用.见:王世真,林汉,周前,主编.核医学与核生物学.北京:科学出版社,1990.141-168.
  • 9Ausubel FM, Brent R, Kingston RE, et al. Short protocols in molecular biology, 3rd ed. New York: John Wiley & Sons Press, 1995, 104-105.
  • 10Liddell JE, Cryer A.A practical guide to monoclonal antibodies. West Sussex:John Wiley & Sons,1991.110-115.

共引文献63

同被引文献25

  • 1于士柱,黄悦,李莉,管欣琴,安同岭.胶质瘤细胞端粒酶基因表达对其增殖及凋亡影响的研究[J].中国神经肿瘤杂志,2005,3(2):82-87. 被引量:6
  • 2薛祥云,刘宁,尤永平.hTERT反义cDNA对人脑胶质瘤细胞的抑制作用[J].中华神经医学杂志,2006,5(7):667-671. 被引量:1
  • 3Kyo S, kanaya T, Takaura M, et al. Human telomerse reverse transcriptase as a critical determinant of telomerase activity in normal and malignant edometrial tissue[J]. Int J Cancer, 1999, 80:60 - 63.
  • 4Takahashi S, Kitamoto M, Takaishi H, et al. Expression of telomerase component genes in hepatocellular carcinomas[J] . Eur J Canaer, 2000, 36(4): 496 - 502.
  • 5Tahara H, Nakanishi T, Kitamoto M, et al. Telomerase activity in human liver tissue: comparison between chronic livei disease and hepatocellular carcinomas[J]. C ancer Res, 1995, 55(13): 2734 - 2736.
  • 6Takaishi H, kitamoto M, Takahashi S, et al. Precancerous hepatic nodules had significant levels of telomerase activity determined by sensitive quantitation using ahybridization protection assay[J]. Cacer, 2000, 88(2): 312 -317.
  • 7Tatsuma T, Goto S, Kitano S, et al. Telomerase activity in peripheral blood for diagnosis of hepatoma[J]. J Gastroenterol Hepatol, 2000, 15(9):1064 - 1070.
  • 8Datar R H, Naritoku W Y, Li P, et al. Analysis of telomerase activity in ovarian cystadenomas, low - malignant - potential tumor, and invasive carcinomas[J]. Gynecol Oncol, 1999, 74(3): 338 - 345.
  • 9Vietor M, Winter S, Groscurth P, et al. On the significance of te- lomerase activity in human malignant glioma cells[ J]. Eur J Phar- macol, 2000,407 ( 1-2 ) : 27 - 37.
  • 10张丽媛,吴铁.人参皂苷Rh_2抗肿瘤作用机制的研究进展[J].安徽农业科学,2008,36(4):1467-1468. 被引量:15

引证文献3

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部